190 related articles for article (PubMed ID: 9873600)
1. Thalidomide analogs and PDE4 inhibition.
Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen Y; Stirling DI
Bioorg Med Chem Lett; 1998 Oct; 8(19):2669-74. PubMed ID: 9873600
[TBL] [Abstract][Full Text] [Related]
2. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors.
Raboisson P; Lugnier C; Muller C; Reimund JM; Schultz D; Pinna G; Le Bec A; Basaran H; Desaubry L; Gaudiot F; Seloum M; Bourguignon JJ
Eur J Med Chem; 2003 Feb; 38(2):199-214. PubMed ID: 12620664
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties.
Reimund JM; Raboisson P; Pinna G; Lugnier C; Bourguignon JJ; Muller CD
Biochem Biophys Res Commun; 2001 Oct; 288(2):427-34. PubMed ID: 11606060
[TBL] [Abstract][Full Text] [Related]
5. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
[No Abstract] [Full Text] [Related]
6. Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Kikkawa H; Ikezawa K; Naito K
Bioorg Med Chem Lett; 2003 Jul; 13(14):2347-50. PubMed ID: 12824031
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes.
Keller TH; Bray-French K; Demnitz FW; Müller T; Pombo-Villar E; Walker C
Chem Pharm Bull (Tokyo); 2001 Aug; 49(8):1009-17. PubMed ID: 11515569
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues.
Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR
J Clin Immunol; 2001 Sep; 21(5):357-64. PubMed ID: 11720008
[TBL] [Abstract][Full Text] [Related]
9. Substituted furans as inhibitors of the PDE4 enzyme.
Perrier H; Bayly C; Laliberté F; Huang Z; Rasori R; Robichaud A; Girard Y; Macdonald D
Bioorg Med Chem Lett; 1999 Feb; 9(3):323-6. PubMed ID: 10091677
[TBL] [Abstract][Full Text] [Related]
10. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
[TBL] [Abstract][Full Text] [Related]
11. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine.
Boichot E; Wallace JL; Germain N; Corbel M; Lugnier C; Lagente V; Bourguignon JJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):647-53. PubMed ID: 10640302
[TBL] [Abstract][Full Text] [Related]
13. Highly potent PDE4 inhibitors with therapeutic potential.
Ochiai H; Ohtani T; Ishida A; Kusumi K; Kato M; Kohno H; Kishikawa K; Obata T; Nakai H; Toda M
Bioorg Med Chem Lett; 2004 Jan; 14(1):207-10. PubMed ID: 14684329
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
15. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
16. Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.
Charpiot B; Brun J; Donze I; Naef R; Stefani M; Mueller T
Bioorg Med Chem Lett; 1998 Oct; 8(20):2891-6. PubMed ID: 9873643
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues.
Lima LM; Castro P; Machado AL; Fraga CA; Lugnier C; de Moraes VL; Barreiro EJ
Bioorg Med Chem; 2002 Sep; 10(9):3067-73. PubMed ID: 12110331
[TBL] [Abstract][Full Text] [Related]
18. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
20. Orally active indole N-oxide PDE4 inhibitors.
Hulme C; Mathew R; Moriarty K; Miller B; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Labaudiniere R; Huang F; Djuric SW
Bioorg Med Chem Lett; 1998 Nov; 8(21):3053-8. PubMed ID: 9873675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]